<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of immune thrombocytopenia (ITP)-associated bleeding in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of immune thrombocytopenia (ITP)-associated bleeding in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of immune thrombocytopenia (ITP)-associated bleeding in adults</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Specialist involvement is appropriate in ITP-associated bleeding to help assess other bleeding risk factors and to advise on use of therapies to increase the platelet count. There may be variation in the platelet count threshold below which different hematologists will initiate different treatments. Patient-specific factors such as age and other bleeding risk factors may also be incorporated into decision-making. A separate algorithm addresses ITP-associated thrombocytopenia without bleeding.<br/>We use the following definitions, with selected examples: 

<ul class="decimal_heading">
<li><strong>Critical bleeding</strong> – Bleeding into a critical anatomical site or bleeding that causes hemodynamic instability or respiratory compromise. Includes intracranial, intraspinal, intraocular, retroperitoneal, pericardial, or intramuscular bleeding with compartment syndrome.</li>
<li><strong>Severe bleeding</strong> – Bleeding that results in a fall in hemoglobin of 2 or more g/dL or requires transfusion of 2 or more units of pRBCs but does not meet the definition of critical bleeding.</li>
<li><strong>Minor bleeding</strong> – Bleeding that does not meet criteria for severe or critical bleeding. Examples include skin bleeding or non-severe mucous membrane bleeding.</li></ul></div><div class="graphic_footnotes">ITP: immune thrombocytopenia; IVIG: intravenous immune globulin; CNS: central nervous system.<br/>* Most cases of critical and severe bleeding occur with a platelet count &lt;20,000/microL; some hematologists use a count of &lt;30,000/microL to attribute bleeding solely to ITP.<br/>¶ Refer to a separate algorithm for additional detail regarding therapy for minor bleeding. The <span style="COLOR: black">glucocorticoid for critical or severe bleeding typically is dexamethasone, 40 mg intravenously once per day for 4 days. Alternative glucocorticoid regimens can be used (eg, methylprednisolone 1 gram intravenously once </span>per day for 3 days for critical bleeding; oral prednisone for minor bleeding). Refer to UpToDate for advantages and disadvantages of different regimens. <br/>∆ Other bleeding risk factors include liver or kidney disease, anticoagulants, antiplatelet agents, other medications that contribute to bleeding risk, and others. These risk factors should be assessed and mitigated as much as possible in combination with ITP treatments.</div><div id="graphicVersion">Graphic 130648 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
